Assessment of Antidiabetic and Anti-Inflammatory Activities of Carissa carandas Linn Extract: In Vitro and In Vivo Study

Abstract

This study investigated the effects of aqueous fruit extracts of Carissa carandas (CCA) on inflammation and insulin resistance using an in vitro cellular model, in vivo high-fat diets, and a streptozotocin-induced type 2 diabetic (T2DM) rat model. CCA significantly ameliorated inflammation by decreasing nitric oxide production in lipopolysaccharide (LPS)-induced RAW 264.7 macrophages. Interestingly, CCA showed anti-insulin resistance activities, as it significantly improved glucose uptake and decreased glycerol release in LPS-induced 3T3-L1 adipocytes. In vivo studies showed that a high dose of 12-week oral supplementation of CCA (400 mg/kg BW/day) significantly reduced visceral fat, triglycerides, and cholesterol level in the blood of diabetic rats. Importantly, the metabolic parameters in both fasting and postprandial states, including fasting plasma glucose, HOMA-IR, and glucose intolerance, significantly improved, indicating its antihyperglycemic benefit in diabetic rats. Moreover, the results of the HOMA-β and histological examination suggested that pancreatic β-cell function and pancreatic morphological changes of the CCA and metformin treatments appeared to be better than those in non-treated diabetes, indicating the protective effect of CCA against pancreatic damage caused by hyperglycemia. In conclusion, the present study first reported that the C. carandas fruit extract has anti-inflammation and anti-insulin resistance, and subsequently improved glycemic control in the T2DM rat model.